The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Pernicious Anemia Diagnosis And Treatment Market From 2026 To 2030?
The pernicious anemia diagnosis and treatment market size has experienced robust expansion in recent times. It is projected to expand from $1.51 billion in 2025 to $1.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. The expansion observed in previous periods is attributable to a high frequency of hospital-acquired infections, the ongoing reliance on conventional IV catheters, an expanding patient demographic in need of IV therapy, the constrained availability of advanced safety catheters, and a fragmented healthcare infrastructure.
The pernicious anemia diagnosis and treatment market size is projected to experience substantial growth in the coming years, reaching $2.09 billion by 2030 at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is primarily driven by advancements in safety IV catheter technologies, the increasing adoption of smart and antimicrobial catheters, the expansion of home healthcare services, a rising preference for integrated/closed IV systems, and the growing demand for minimally invasive therapy administration. Key trends expected within the forecast period include the increasing adoption of AI-based catheter insertion guidance systems, a rising use of cloud-based patient monitoring for IV therapy, the ongoing development of antimicrobial and smart catheters, increased integration of IoT-enabled devices for IV monitoring, and the rising implementation of smart manufacturing for peripheral IV catheters.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
What Major Drivers Are Influencing Demand In The Pernicious Anemia Diagnosis And Treatment Market?
The increasing occurrence of vitamin B12 deficiency is anticipated to fuel expansion in the pernicious anemia diagnosis and treatment market in the future. This deficiency arises when the body doesn’t possess sufficient B12 to generate enough red blood cells, resulting in symptoms like tiredness, lack of strength, and nerve-related problems. The uptick in vitamin B12 deficiency is linked to the growing popularity of plant-based eating patterns, which frequently do not provide enough natural B12 and can cause insufficient consumption without appropriate supplements. Low B12 levels directly hinder red blood cell creation, thereby underpinning the diagnosis and treatment of pernicious anemia by prompting medical professionals to utilize B12 supplementation as a key and successful therapeutic approach. For example, a report released by the National Health Service (NHS), a UK-based government health organization, in February 2023 indicated that deficiencies in both vitamin B12 and folate are more common among older adults, impacting approximately 1 in 10 individuals 75 years of age or older and 1 in 20 of those 65 to 74 years of age. Consequently, the increasing incidence of vitamin B12 deficiency is propelling the expansion of the pernicious anemia diagnosis and treatment market.
Which Segments Are Included In The Analysis Of The Pernicious Anemia Diagnosis And Treatment Market?
The pernicious anemia diagnosis and treatment market covered in this report is segmented –
1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray
3) By Route Of Administration: Injection, Oral, Intranasal
4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test
Which Market Trends Are Creating New Opportunities In The Pernicious Anemia Diagnosis And Treatment Market?
Leading companies within the pernicious anemia diagnosis and treatment market are prioritizing the development of innovative solutions, such as vitamin B12 maintenance therapy options, to enhance patient adherence and long-term disease management. These vitamin B12 maintenance therapy solutions typically involve consistent, ongoing supplementation through oral tablets, injections, or nasal sprays to sustain adequate B12 levels and prevent the recurrence of deficiency-related symptoms. For instance, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, introduced a cyanocobalamin nasal spray, 500 mcg/spray, as a non-invasive alternative for vitamin B12 supplementation. This nasal spray offers a convenient and effective method for patients suffering from pernicious anemia who face challenges with oral vitamin B12 forms. It helps improve B12 absorption and supports the management of vitamin B12 deficiency, ultimately boosting patient compliance and overall treatment outcomes.
Which Key Industry Participants Are Active In The Pernicious Anemia Diagnosis And Treatment Market?
Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, Bio-Techne Corporation
Read the full pernicious anemia diagnosis and treatment market report here:
Which Region Shows The Strongest Potential For Future Growth In The Pernicious Anemia Diagnosis And Treatment Market?
North America was the largest region in the pernicious anemia diagnosis and treatment market in 2025. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pernicious Anemia Diagnosis And Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp
Browse Through More Reports Similar to the Global Pernicious Anemia Diagnosis And Treatment Market 2026, By The Business Research Company
Hemodialysis And Peritoneal Dialysis Global Market Report
Portable Dialysis Machines Global Market Report
https://www.thebusinessresearchcompany.com/report/portable-dialysis-machines-global-market-report
Dialysis Catheters Global Market Report
https://www.thebusinessresearchcompany.com/report/dialysis-catheters-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model